Skip to main content
Clinical Trials/NCT00693251
NCT00693251
Completed
Phase 4

Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions

Seung-Jung Park11 sites in 1 country420 target enrollmentJanuary 2008

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Seung-Jung Park
Enrollment
420
Locations
11
Primary Endpoint
Angiographic binary restenosis rate (diameter stenosis >= 50%) at 8 months in either main or side branch
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

It is unclear which stenting strategy will be optimal for true bifurcation coronary lesions.

Detailed Description

The outcome of percutaneous coronary intervention of bifurcation lesions with bare-metal stents is hindered by increased rates of procedural complications and long-term major adverse cardiac events compared with non-bifurcated lesions.1 Randomized studies have demonstrated that drug-eluting stents reduce restenosis when used in relatively simple lesions; and recent data have demonstrated efficacy of the sirolimus-eluting stent for bifurcation lesions compared with historical data of BMS. In one study of bifurcation lesions, the overall restenosis rate was 23%, with the majority of side branch restenoses occurring at the ostium after use of a T-stenting technique. Indeed, side branch restenosis occurred in 16.7% after T-stenting, compared with 7.1% after other stenting techniques. The "crush" technique of bifurcation stenting with DESs was introduced by Colombo et al. in 2003 as a relatively simple technique that ensures complete coverage of the side branch ostium, thereby facilitating drug delivery at this site. Initial data of 20 patients treated with this technique with SES suggest that it is a safe method, with an acceptable rate of procedural complications and no further adverse events up to 30 days follow-up. Recently, angiographic data have shown the importance of simultaneous kissing balloon post-dilation in reducing restenosis and need for target lesion revascularization. They also reported that compared to T-stenting, crushing with final kissing balloon dilatation was associated with lower rate of restenosis and target lesion revascularization. Consequently, the crushing is currently most promising technique in treating bifurcation lesions using two stents. However, despite the advance of bifurcation stenting technique, the superiority of bifurcation stenting with crushing technique over simple stenting in bifurcation lesion has not been demonstrated. Therefore, we conducted the prospective randomized study comparing crushing technique with final kissing balloon dilatation and a simple technique (main vessel stenting and provisional T-stenting) for treatment of true bifurcation lesions.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
June 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Seung-Jung Park
Responsible Party
Sponsor Investigator
Principal Investigator

Seung-Jung Park

MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine

CardioVascular Research Foundation, Korea

Eligibility Criteria

Inclusion Criteria

  • Patients with angina and documented ischemia or patients with documented silent ischemia
  • Patients who are eligible for intracoronary stenting
  • Age \>18 years, \<75 ages
  • Angiographic
  • De novo lesion located in a major bifurcation point with the MEDINA classification type 1.1.0, 1.0.0, or 0.1.0
  • Main vessel : \>= 2.5 mm in vessel size, \>= 50% in diameter stenosis and =\< 50 mm in lesion length by visual estimation, in which the lesion seems to be covered with =\< 2 stents
  • Side branch : \>= 2.0 mm in vessel size, \>= 50% in diameter stenosis, and \< 20 mm in lesion length by visual estimation, in which the lesion seems to be covered with single stent

Exclusion Criteria

  • History of bleeding diathesis or coagulopathy
  • Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and paclitaxel
  • Limited life-expectancy (less than 1 year) due to combined serious disease
  • ST-elevation acute myocardial infarction \< 2 weeks
  • Characteristics of lesion:
  • Left main disease
  • In-stent restenosis
  • Graft vessels
  • Chronic total occlusion
  • TIMI flow =\< grade 2 in the side branch

Outcomes

Primary Outcomes

Angiographic binary restenosis rate (diameter stenosis >= 50%) at 8 months in either main or side branch

Time Frame: 8 months

Secondary Outcomes

  • Influence of bifurcation angle(8 months)
  • Amount of contrast agent(baseline)
  • FFR assessment in the side branch(baseline and 8 months)
  • Influence of new three segment bifurcation QCA software(8 months)
  • Fluoroscopic time(baseline)
  • Procedure time(baseline)
  • Reocclusion rate at the side branch at 8 month angiographic follow-up(8 months)
  • Restenosis rate at the main vessel and/or side branch(8 months)
  • Number of used stents(baseline)
  • Composite of major cardiac adverse events (MACE) including death, MI, stent thrombosis and ischemia-driven target vessel revascularization(2 years)
  • Late loss at the main vessel and the side branch(8 months)

Study Sites (11)

Loading locations...

Similar Trials